Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results

Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results

* Fanapt(® )Q2 2026 net product sales increased 23% to $36.0 million; total prescriptions increased 31% * Full-year 2026 total revenue guidance of $240-$290 million * Cash totaled $170.0 million as of June 30, 2026; expected to fund operations through at least the end of 2027 * BYSANTI™ (milsaperidone) received FDA approval for bipolar I disorder and schizophrenia in Q1 2026; commercial launch expected in second half of 2026 * Quimilza™ (imsidolimab) BLA for GPP under review by the FDA; PDUFA target action date of December 12, 2026 * NEREUS™ for prevention of vomiting induced by motion became commercially available in Q2 2026 * Results for three Phase III clinical trials expected by end of 2026: * NEREUS™ (tradipitant) in vomiting in GLP-1, * VQW-765 in social anxiety disorder * HETLIOZ(®) (tasimelteon) in delayed sleep phase disorder WASHINGTON, Aug. 5, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2026.